Experic

Articles

Experic’s latest article looks at new initiatives aimed at fostering the development of biologics delivered via inhalation, an emerging field. While manufacturing technologies have advanced to support this sector, several challenges remain, including an unclear regulatory pathway.

Inhaled Biologics from Zero

Experic talks about how biopharmaceutical companies can leverage CDMO collaborations to mitigate risks and maximize the benefits of key drug development decisions. 

Making Key Decisions for Efficient and Cost-Effective Biopharmaceutical Drug Development Programs

A convenient checklist from the experts at Experic to jump-start your planning so supply challenges won’t hinder your progress! Download the checklist today and take advantage of Experic's expert tips to optimize your clinical trial supply planning.

Clinical Trial Supplies Planning Checklist

Discover how Experic's state-of-the-art spray drying service can control the formation of consistent particles for DPI therapeutics and increase control over the resulting properties of the powder.


From Spray Drying to DP - Managing Particles for Optimal Delivery to the Lungs

Learn about the biggest trends impacting small-molecule APIs, excipients, and formulations, key sessions to attend while at CPHI, innovations and novel approaches for pediatric dosage forms and taste-masking, and fundamental aspects of API manufacturing and distribution from a panel of experts who have contributed to this year’s CPHI Annual Report, David Tisi from Synopsys, and an SME from C2 Pharma in this episode of the PharmTech Drug Digest Video Series.

https://www.pharmtech.com/pt_w/big-impact

In this exclusive Drug Digest video interview, Felicity Thomas, Europe/senior editor, 

Group, interviews experts about small-molecule APIs, excipients, and formulation advances. During the video session, a panel of experts—Bikash Chatterjee, Tara Dougal —deliberate on the biggest trends impacting the industry, highlighting issues such as API supply and shortages, uptake in digital innovations, formulation advances to deal with potent compounds, and key sessions to visit while at CPHI. Additionally, David Tisi, director of Technical Operations, Synopsys, discusses novel approaches and solutions to pediatric formulations and taste-masking, while an expert from C2 Pharma highlights the fundamental stages of gaining a certificate of suitability for APIs and the various trends shaping API and complex compound manufacturing.
Interviews featuring:

Bikash Chatterjee, president and chief science officer at PharmTech Associates

Tara Dougal, content director—Pharma, Informa Markets

Tara Fitzpatrick, head of Quality, C2 Pharma

This episode of Drug Digest is sponsored by:

Trends impacting small-molecule APIs, excipients, and formulation markets.

Innovations benefitting API and excipient developers and formulation scientists.

Novel approaches to pediatric formulations.

Fundamental stages of gaining a certificate of suitability.


Director of Technical Operations
Synopsys


Webcasts

Webinar Date/Time: Thursday, September 21, 2023 at 11am ET | 10am CT | 8am PT | 4 pm BST

A Big Impact: Trends Shaping Small-Molecule APIs, Excipients, and Formulations

In this Drug Digest video, our speakers will discuss CDMOs and their ever-changing role in the biopharma space and current barriers in cell and gene therapy (CGT) manufacturing. Join the Drug Digest video to help prepare for manufacturing and cell/gene therapy challenges. Learn how digitalization, CDMOs, and CGT relate to conventional biopharma development and manufacturing.

https://www.pharmtech.com/pt_w/accelerating-biopharma

The biopharmaceutical industry has seen a lot of change in recent years, between new collaborations with supplier and contract development and manufacturing organizations (CDMOs) and accelerated drug delivery times. According to recent research, biopharmaceutical figures are already using digital and analytics for their benefit, with an increase of up to 40% in plant capacity, 20% in lead time, and 15% reduction in conversion costs (1).


With more growth comes more responsibilities, and processes like cell and gene therapy are on the forefront for the latest strategies to overcome the challenges in the manufacturing space.
In this Drug Digest video, Anil Kane, Global Head of Technical and Scientific Affairs, Pharma Services at Thermo Fisher Scientific, and Jason C. Foster, CEO and executive director at Ori Biotech, will provide expert insights into what happens in the manufacturing space from a CDMO and a cell/gene therapy perspective.

Reimagining the future of biopharma manufacturing

. October 11, 2022. https://www.mckinsey.com/industries/life-sciences/our-insights/reimagining-the-future-of-biopharma-manufacturing

The ability to identify the benefits of biopharma companies partnering with a CDMO

The ability to learn about different kinds of cell and gene therapies and how to overcome the barriers in the continuous manufacturing space

Problem solving: ability to develop a plan for concepts, such as scalability and being more cost efficient, with new products and techniques

Awareness: ability to successfully pinpoint new approaches to medicine and how to respond as a biopharma company


Global Head of Technical and Scientific Affairs
Pharma Services at Thermo Fisher Scientific

Webinar Date/Time: Thu, Jul 20, 2023 11:00 AM EDT
